These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8480584)

  • 21. [Evaluation of myocardial energy metabolism by 31 P-magnetic resonance spectroscopy in patients with hypertrophic cardiomyopathy versus healthy individuals].
    Mazaev VV; Stukalova OV; Ternovoĭ SK; Chazova IE
    Vestn Rentgenol Radiol; 2012; (6):8-12. PubMed ID: 23520935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors improve myocardial high-energy phosphate metabolism in men.
    Schocke MF; Martinek M; Kremser C; Wolf C; Steinboeck P; Lechleitner M; Jaschke W; Pachinger O; Metzler B
    J Cardiovasc Magn Reson; 2003; 5(4):595-602. PubMed ID: 14664137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction.
    Dass S; Cochlin LE; Suttie JJ; Holloway CJ; Rider OJ; Carden L; Tyler DJ; Karamitsos TD; Clarke K; Neubauer S; Watkins H
    Eur Heart J; 2015 Jun; 36(24):1547-54. PubMed ID: 25990345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR spectroscopy of the heart.
    Sardanelli F; Quarenghi M
    Radiol Med; 2006 Dec; 111(8):1025-34. PubMed ID: 17171530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy.
    Pluim BM; Lamb HJ; Kayser HW; Leujes F; Beyerbacht HP; Zwinderman AH; van der Laarse A; Vliegen HW; de Roos A; van der Wall EE
    Circulation; 1998 Feb; 97(7):666-72. PubMed ID: 9495302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy.
    Neubauer S; Horn M; Pabst T; Harre K; Strömer H; Bertsch G; Sandstede J; Ertl G; Hahn D; Kochsiek K
    J Investig Med; 1997 Oct; 45(8):453-62. PubMed ID: 9394098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation of regional wall motion and fatty acid metabolism in coronary artery disease, hypertension, and hypertrophic cardiomyopathy: assessment by dual-isotope SPECT with thallium-201 and iodine-123 beta-methyl fatty acid analogue].
    Hase M; Nakata T; Yonekura S; Tsuchihashi K; Kobayashi H; Nagao K; Tanaka S; Kubota M; Tsuda T; Iimura O
    Kaku Igaku; 1993 May; 30(5):529-39. PubMed ID: 8336412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of altered myocardial high energy phosphate metabolism in patients on maintenance dialysis using phosphorus-31 magnetic resonance spectroscopy.
    Tagami T; Sakuma H; Matsumura K; Takeda K; Mori S; Takeuchi T; Nakano T
    Invest Radiol; 1998 Mar; 33(3):171-6. PubMed ID: 9525756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The quantification of energy-rich phosphates in healthy and damaged heart muscle by SLOOP 31P-MR spectroscopy. Spatial localization with optimal pointspread function].
    Beer M; Landschütz W; Meininger M; Seyfarth T; Viehrig M; Sandstede J; Pabst T; Kenn W; Horn M; Harre K; von Kienlin M; Neubauer S; Hahn D
    Rofo; 1999 Jul; 171(1):65-8. PubMed ID: 10464508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 31P MRS of myocardial inorganic phosphate using radiofrequency gradient echoes.
    Gober JR; Schwartz GG; Schaefer S; Massie BM; Matson GB; Weiner MW; Karczmar GS
    Magn Reson Med; 1991 Aug; 20(2):171-83. PubMed ID: 1775045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of rapid-sequence 31P magnetic resonance spectroscopy in cardiac patients.
    Chida K; Otani H; Saito H; Nagasaka T; Kagaya Y; Kohzuki M; Zuguchi M; Shirato K
    Acta Radiol; 2005 Jul; 46(4):386-90. PubMed ID: 16134315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of myocardial perfusion and ventricular shape in hypertrophic cardiomyopathy using 99mTc-tetrofosmin scintigraphy: comparison with 201Tl myocardial scintigraphy].
    Ohtsuki K; Sugihara H; Taniguchi Y; Umamoto I; Nakagawa T; Nakamura T; Azuma A; Kohno Y; Adachi H; Ochiai M
    Kaku Igaku; 1994 Apr; 31(4):309-18. PubMed ID: 8196227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies--the study using ECG gated MR spectroscopy with a localization technique.
    Masuda Y; Tateno Y; Ikehira H; Hashimoto T; Shishido F; Sekiya M; Imazeki Y; Imai H; Watanabe S; Inagaki Y
    Jpn Circ J; 1992 Jun; 56(6):620-6. PubMed ID: 1625368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between exercise-induced myocardial ischemia and reduced left ventricular distensibility in patients with nonobstructive hypertrophic cardiomyopathy.
    Isobe S; Izawa H; Takeichi Y; Nonokawa M; Nanasato M; Ando A; Kato K; Ikeda M; Murohara T; Yokota M
    J Nucl Med; 2003 Nov; 44(11):1717-24. PubMed ID: 14602851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging.
    Huang X; Yue Y; Wang Y; Deng Y; Liu L; Di Y; Sun S; Chen D; Fan L; Cao J
    Cardiovasc Ultrasound; 2018 Oct; 16(1):23. PubMed ID: 30285887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Griffey RH; Brown MS; Bankhurst AD; Sibbitt RR; Sibbitt WL
    Arthritis Rheum; 1990 Jun; 33(6):827-33. PubMed ID: 2363738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial metabolic changes in hypertrophic cardiomyopathy.
    Tadamura E; Tamaki N; Matsumori A; Magata Y; Yonekura Y; Nohara R; Sasayama S; Yoshibayashi M; Kamiya T; Konishi J
    J Nucl Med; 1996 Apr; 37(4):572-7. PubMed ID: 8691242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gadolinium-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging of dilated cardiomyopathy: clinical significance of abnormally high signal intensity of left ventricular myocardium].
    Koito H; Suzuki J; Ohkubo N; Ishiguro Y; Iwasaka T; Inada M
    J Cardiol; 1996 Jul; 28(1):41-9. PubMed ID: 8768505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo mouse myocardial (31)P MRS using three-dimensional image-selected in vivo spectroscopy (3D ISIS): technical considerations and biochemical validations.
    Bakermans AJ; Abdurrachim D; van Nierop BJ; Koeman A; van der Kroon I; Baartscheer A; Schumacher CA; Strijkers GJ; Houten SM; Zuurbier CJ; Nicolay K; Prompers JJ
    NMR Biomed; 2015 Oct; 28(10):1218-27. PubMed ID: 26269430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy.
    Meininger M; Landschütz W; Beer M; Seyfarth T; Horn M; Pabst T; Haase A; Hahn D; Neubauer S; von Kienlin M
    Magn Reson Med; 1999 Apr; 41(4):657-63. PubMed ID: 10332840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.